14 September 2017 - Government is considering whether to review prices annually.

Japan’s effort to rein in soaring health-care costs threatens to become a source of tension in economic relations with the U.S. after running into opposition from the American pharmaceutical industry.

While the U.S. Commerce Department sees Japan’s drug market, the world’s third largest, as the top near-term growth opportunity for its pharmaceutical exporters, the view from Tokyo is of crippling medical bills as the ranks of the elderly swell and the working-age population declines.

Read Bloomberg article